H-1B sponsorship profile: Oncopia Therapeutics, Inc. Across U.S. Department of Labor LCA disclosures, Oncopia Therapeutics, Inc filed 4 Labor Condition Applications covering 4 H-1B worker positions between fiscal year 2023 and fiscal year 2024. The employer’s DOL certification rate sits at 75% (3 certified of 4 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Oncopia Therapeutics, Inc’s H-1B petitions range from $125,000 at the low end to $170,000 at the high end, with a petition-weighted average of $136,992. That range reflects the mix of occupations the company sponsors, led by Scientist, Biology (3 petitions at $125,990 avg), followed by Principal Scientist/Assistant Director, Proteomics. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Oncopia Therapeutics, Inc is headquartered in New York, PA under NAICS code 32541, and places H-1B workers across 1 state, most heavily in PA. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Oncopia Therapeutics, Inc ranks. By H-1B petition volume, Oncopia Therapeutics, Inc is #30,742 of 119,880 employers nationally and #915 of 3,282 employers headquartered in PA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.